CA1298784C - Pharmaceutical formulations with controlled release of the active substance - Google Patents

Pharmaceutical formulations with controlled release of the active substance

Info

Publication number
CA1298784C
CA1298784C CA000519302A CA519302A CA1298784C CA 1298784 C CA1298784 C CA 1298784C CA 000519302 A CA000519302 A CA 000519302A CA 519302 A CA519302 A CA 519302A CA 1298784 C CA1298784 C CA 1298784C
Authority
CA
Canada
Prior art keywords
formulation according
isradipine
formulation
controlled release
fatty material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000519302A
Other languages
English (en)
French (fr)
Inventor
Othmar Zuger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858524135A external-priority patent/GB8524135D0/en
Priority claimed from GB858524653A external-priority patent/GB8524653D0/en
Priority claimed from GB858531419A external-priority patent/GB8531419D0/en
Priority claimed from GB868603097A external-priority patent/GB8603097D0/en
Priority claimed from GB868605037A external-priority patent/GB8605037D0/en
Application filed by Sandoz AG filed Critical Sandoz AG
Application granted granted Critical
Publication of CA1298784C publication Critical patent/CA1298784C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA000519302A 1985-10-01 1986-09-29 Pharmaceutical formulations with controlled release of the active substance Expired - Lifetime CA1298784C (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB858524135A GB8524135D0 (en) 1985-10-01 1985-10-01 Darodipine compositions
GB8524135 1985-10-01
GB858524653A GB8524653D0 (en) 1985-10-07 1985-10-07 Pharmaceutical formulations
GB8524653 1985-10-07
GB8531419 1985-12-20
GB858531419A GB8531419D0 (en) 1985-12-20 1985-12-20 Pindolol compositions
GB8603097 1986-02-07
GB868603097A GB8603097D0 (en) 1986-02-07 1986-02-07 Pharmaceutical formulations
GB8605037 1986-02-28
GB868605037A GB8605037D0 (en) 1986-02-28 1986-02-28 Oral pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CA1298784C true CA1298784C (en) 1992-04-14

Family

ID=27516617

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000519302A Expired - Lifetime CA1298784C (en) 1985-10-01 1986-09-29 Pharmaceutical formulations with controlled release of the active substance

Country Status (20)

Country Link
KR (1) KR920008817B1 (enExample)
AT (1) AT402257B (enExample)
BE (1) BE905516A (enExample)
CA (1) CA1298784C (enExample)
CH (1) CH669524A5 (enExample)
DE (1) DE3632201C2 (enExample)
DK (1) DK170016B1 (enExample)
ES (1) ES2002508A6 (enExample)
FR (1) FR2589732B1 (enExample)
GR (1) GR862457B (enExample)
HK (1) HK392A (enExample)
HU (1) HU197201B (enExample)
IE (1) IE59589B1 (enExample)
IL (1) IL80182A (enExample)
LU (1) LU86615A1 (enExample)
NL (1) NL194822C (enExample)
NZ (1) NZ217732A (enExample)
PT (1) PT83456B (enExample)
SE (1) SE503222C2 (enExample)
SG (1) SG103391G (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
WO2003065970A2 (en) * 2001-02-20 2003-08-14 Royal College Of Surgeons Ie Treatment of fibromyalgia and related fatigue syndromes using pindolol
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
DD145004A3 (de) * 1978-09-25 1980-11-19 Reinhard Huettenrauch Verfahren zur herstellung fester a zneiformen
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS6056122B2 (ja) * 1980-05-21 1985-12-09 塩野義製薬株式会社 徐放性製剤
GB2084017B (en) * 1980-09-18 1984-08-22 Sandoz Ltd Pharmaceutical compositions effective against coronary heat disease and hypertension
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions
JPS61501511A (ja) * 1984-03-21 1986-07-24 アメリカン・ホ−ム・プロダクツ・コ−ポレイション 徐放性医薬カプセル
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤

Also Published As

Publication number Publication date
AT402257B (de) 1997-03-25
HUT44701A (en) 1988-04-28
IL80182A0 (en) 1986-12-31
DE3632201A1 (de) 1987-04-02
DE3632201C2 (de) 1997-05-07
KR870003777A (ko) 1987-05-04
IL80182A (en) 1991-01-31
IE59589B1 (en) 1994-03-09
SG103391G (en) 1992-01-17
DK170016B1 (da) 1995-05-01
LU86615A1 (fr) 1987-04-02
GR862457B (en) 1987-01-29
NL194822C (nl) 2003-04-03
DK464686D0 (da) 1986-09-29
SE8604112L (sv) 1987-04-02
ATA260486A (de) 1996-08-15
HU197201B (en) 1989-03-28
ES2002508A6 (es) 1988-08-16
IE862565L (en) 1987-04-01
NZ217732A (en) 1990-07-26
PT83456A (en) 1986-10-01
DK464686A (da) 1987-04-02
PT83456B (pt) 1989-05-12
SE8604112D0 (sv) 1986-09-29
NL194822B (nl) 2002-12-02
FR2589732A1 (fr) 1987-05-15
NL8602370A (nl) 1987-05-04
HK392A (en) 1992-01-10
KR920008817B1 (ko) 1992-10-09
SE503222C2 (sv) 1996-04-22
FR2589732B1 (fr) 1989-07-13
CH669524A5 (enExample) 1989-03-31
BE905516A (fr) 1987-03-30

Similar Documents

Publication Publication Date Title
US12239615B2 (en) Hydroxynorketamine for the use in the treatment of depression
AU744071B2 (en) Sustained release ranolazine formulations
AU2001240092B2 (en) Sustained release ranolazine formulations
HU210461A9 (en) Pharmaceutical composition for prolongated release of a dihydropyridine and a beta-adrenoreceptor antagonist and process for producing the composition
EP0746317A1 (en) Sublingual or buccal pharmaceutical composition
US5399360A (en) Pharmaceutical compositions
EP1404304B1 (en) Tablet comprising cetirizine and pseudoephedrine
RU2213560C2 (ru) Фармацевтическая композиция, содержащая сочетание правовращающего и левовращающего изомеров соталола
GB2181053A (en) Controlled release formulation
GB2154874A (en) Bromocriptine compositions
US7226614B2 (en) Tablet comprising cetirizine and pseudoephedrine
GB2170407A (en) Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
KR920008817B1 (ko) 조절된 방출성(서방성) 약학적 제제의 제조방법.
US5069911A (en) Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
AU598751B2 (en) Pharmaceutical formulations with controlled release of the active substance
HU196121B (en) Process for production of medical compounds containing brome-cryptin and assuring regulated release of the active substance
JPS62149618A (ja) 活性物質放出制御医薬製剤
JPS61183221A (ja) ３‐アミノプロポキシインドール類含有医薬組成物
MXPA96003713A (en) Sublingual pharmaceutical composition or bu
HK1064596B (en) Tablet comprising cetirizine and pseudoephedrine

Legal Events

Date Code Title Description
MKEX Expiry